These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 21289270

  • 1. Osteoporosis medication and reduced mortality risk in elderly women and men.
    Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1006-14. PubMed ID: 21289270
    [Abstract] [Full Text] [Related]

  • 2. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser S, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR, CaMOS Research Group.
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [Abstract] [Full Text] [Related]

  • 3. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E.
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
    Ström O, Landfeldt E, Garellick G.
    Osteoporos Int; 2015 Jan; 26(1):315-25. PubMed ID: 25297890
    [Abstract] [Full Text] [Related]

  • 8. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
    Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group.
    J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
    [Abstract] [Full Text] [Related]

  • 9. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study.
    Bliuc D, Alarkawi D, Nguyen TV, Eisman JA, Center JR.
    J Bone Miner Res; 2015 Apr; 30(4):637-46. PubMed ID: 25359586
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S, Dragomir A, Desgagné A, Blais L, Rossignol M, Blouin J, Moride Y, Ste-Marie LG, Fernandès JC.
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [Abstract] [Full Text] [Related]

  • 12. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
    Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH.
    South Med J; 2006 Jun; 99(6):570-5. PubMed ID: 16800411
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E, Puglisi N, Mamazza C, Lo Giudice F, Testai M, Abbate S, Santangelo A, Panebianco P, Maugeri D.
    Eur Rev Med Pharmacol Sci; 2004 Jun; 8(2):97-102. PubMed ID: 15267123
    [Abstract] [Full Text] [Related]

  • 15. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
    McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA.
    J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717
    [Abstract] [Full Text] [Related]

  • 16. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk of atypical femoral fracture during and after bisphosphonate use.
    Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K.
    Acta Orthop; 2015 Feb 13; 86(1):100-7. PubMed ID: 25582459
    [Abstract] [Full Text] [Related]

  • 19. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
    Abrahamsen B, Rubin KH, Eiken PA, Eastell R.
    Osteoporos Int; 2013 Jan 13; 24(1):321-8. PubMed ID: 23070480
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM.
    Am Fam Physician; 2004 Oct 01; 70(7):1293-300. PubMed ID: 15508540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.